Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504

Mol Cancer, 2014, 15:30

PubMed: 24927996

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed:

Oncotarget, 2015, 51: S659-S660

PubMed:

Julius Maximilians Universit, 2014, Kumari G

PubMed:

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	NWLjfFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TGbWlEPTB;MD6wNFA{ODNizszN	NYfjUIdZW0GQR1XS
IST-MEL1	NWnHcnVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHmSG1VUUN3ME2wMlAxODRyNzFOwG0>	MojDV2FPT0WU
NCI-SNU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTab4IyUUN3ME2wMlAxOjB5IN88US=>	NEfWPVZUSU6JRWK=
FADU	NXfsV4k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMECyNFkh\|ryP	NVnDe2ZLW0GQR1XS
C32	NIjYd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMECzNFQh\|ryP	NGHwenpUSU6JRWK=
D-566MG	NF7GT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwMECzPUDPxE1?	MVLTRW5ITVJ?
LXF-289	M4\qNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3qeJZKSzVyPUCuNFA1OTlizszN	M3rONXNCVkeHUh?=
HGC-27	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEC1NUDPxE1?	M3;u[3NCVkeHUh?=
RPMI-7951	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMEC3NVch\|ryP	MUjTRW5ITVJ?
HSC-3	NITyRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnz5TWM2OD1yLkCwPVI6KM7:TR?=	NEXLS2JUSU6JRWK=
MIA-PaCa-2	NGLG[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEGwNFkh\|ryP	M1vKfHNCVkeHUh?=
KS-1	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorRTWM2OD1yLkCxN\|U2KM7:TR?=	MX3TRW5ITVJ?
CAL-51	NISwbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;NTWM2OD1yLkCxOFA2KM7:TR?=	M1fRfnNCVkeHUh?=
MDA-MB-361	NX3SN\|NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M335SGlEPTB;MD6wNVQ6PSEQvF2=	MVrTRW5ITVJ?
TI-73	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrUVZJXUUN3ME2wMlAyPzl4IN88US=>	MnPKV2FPT0WU
AGS	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XuZmlEPTB;MD6wNVk{QCEQvF2=	NYXkOHVFW0GQR1XS
NCI-H460	MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojITWM2OD1yLkCxPVc1KM7:TR?=	NIjBflJUSU6JRWK=
A204	M1Hyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULZcnpLUUN3ME2wMlAzOjR7IN88US=>	NFv6PFNUSU6JRWK=
CHL-1	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rPemlEPTB;MD6wNlI2OSEQvF2=	MkDGV2FPT0WU
DU-4475	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\6TWM2OD1yLkCyNlYyKM7:TR?=	M4rmSnNCVkeHUh?=
CGTH-W-1	NFyxXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XlW2lEPTB;MD6wNlM1QSEQvF2=	NX;JOGpmW0GQR1XS
HCC2218	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjnTWM2OD1yLkCyOFk1KM7:TR?=	MUjTRW5ITVJ?
A2780	M3L3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Pm[GlEPTB;MD6wNlU{OSEQvF2=	NWTVfm1xW0GQR1XS
NCI-H720	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f6XmlEPTB;MD6wNlU1PiEQvF2=	MkPwV2FPT0WU
NCI-N87	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XRN2lEPTB;MD6wNlU6OyEQvF2=	MnuwV2FPT0WU
CHP-212	M{nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEK2Nlgh\|ryP	MXvTRW5ITVJ?
NCI-H23	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwMEK2OlUh\|ryP	MkfyV2FPT0WU
D-263MG	NWLMOnVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HkNmlEPTB;MD6wNlc5PiEQvF2=	NFyyOJZUSU6JRWK=
ME-180	NUHqVIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m1W2lEPTB;MD6wNlg6OSEQvF2=	M2jvbHNCVkeHUh?=
SW982	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrrb5BKSzVyPUCuNFI6QTlizszN	NUnxXVZ7W0GQR1XS
OE19	NXriUZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmOyTWM2OD1yLkCzNFc4KM7:TR?=	NGqyWJhUSU6JRWK=
SK-LU-1	MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\4VmlEPTB;MD6wN\|A5OiEQvF2=	M{\RcnNCVkeHUh?=
H4	NUDsXGdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33YNGlEPTB;MD6wN\|A6KM7:TR?=	MVvTRW5ITVJ?
HT-144	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrtTWM2OD1yLkCzNFk{KM7:TR?=	NUnqXYhsW0GQR1XS
SK-UT-1	NFfHWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXOxSI9QUUN3ME2wMlA{OTd6IN88US=>	NVHqZ3FjW0GQR1XS
D-336MG	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMEOzNFkh\|ryP	MWXTRW5ITVJ?
MDA-MB-175-VII	M4LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3mdGFKSzVyPUCuNFM{PTRizszN	MoTXV2FPT0WU
GAMG	NVHCZ2hzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fQZ2lEPTB;MD6wN\|Q{PSEQvF2=	NXzaTpJxW0GQR1XS
CP50-MEL-B	NYnmdlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjZTWM2OD1yLkCzOFUh\|ryP	MWPTRW5ITVJ?
OVCAR-5	Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMEO0PEDPxE1?	MWTTRW5ITVJ?
SK-MES-1	NYHoRpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEO2NFYh\|ryP	NYHxcHhSW0GQR1XS
VM-CUB-1	M1X3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HXOWlEPTB;MD6wN\|Y2PyEQvF2=	M1;tN3NCVkeHUh?=
WM-115	NH3wOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7LNYlKSzVyPUCuNFM4PjJizszN	NYW4UWZGW0GQR1XS
DSH1	M4nJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEO4NFch\|ryP	MV;TRW5ITVJ?
Becker	M3q3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PLdWlEPTB;MD6wN\|g5PSEQvF2=	M1HIV3NCVkeHUh?=
SW962	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvz[G1KSzVyPUCuNFM6PDVizszN	NIjybnVUSU6JRWK=
TYK-nu	NGnHfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjPTWM2OD1yLkCzPVg2KM7:TR?=	M4K1ZnNCVkeHUh?=
HO-1-N-1	NHH4dIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3jbplKSzVyPUCuNFQxOjFizszN	M{jZ[HNCVkeHUh?=
T98G	NUfhOnE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLwVHhKSzVyPUCuNFQyODNizszN	Mn;MV2FPT0WU
ACN	NV7lOnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L4dWlEPTB;MD6wOFE3OiEQvF2=	NWWw[2M5W0GQR1XS
SW780	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMESyNFMh\|ryP	M1fuOnNCVkeHUh?=
Detroit562	M1K4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrrTWM2OD1yLkC0NlM6KM7:TR?=	M{L3VHNCVkeHUh?=
BB49-HNC	M1fpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMESyOFMh\|ryP	M{CwOHNCVkeHUh?=
HN	M3LqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPDV4pxUUN3ME2wMlA1Ojd{IN88US=>	MkT2V2FPT0WU
H9	M1HYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLqTWM2OD1yLkC0N\|cyKM7:TR?=	M3ewNnNCVkeHUh?=
VA-ES-BJ	NYe3fYl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjQPXlKSzVyPUCuNFQ1PDdizszN	MULTRW5ITVJ?
MEL-JUSO	NWn4XVNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTyRoRKSzVyPUCuNFQ1PzVizszN	NWjLe5BiW0GQR1XS
BT-474	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTBwMES1JO69VQ>?	MYPTRW5ITVJ?
CaR-1	NWjFbZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL1c4tZUUN3ME2wMlA1PTR7IN88US=>	NVrHeI9iW0GQR1XS
PSN1	MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMES2NFMh\|ryP	MWrTRW5ITVJ?
KYSE-510	M{XCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKyTWM2OD1yLkC0OlQ6KM7:TR?=	NH;PeWRUSU6JRWK=
KP-4	NXLreWg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\nVmN{UUN3ME2wMlA1PzV\|IN88US=>	NH3zcWxUSU6JRWK=
KYSE-410	NXX3XGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLnTWM2OD1yLkC0O\|czKM7:TR?=	Mmm4V2FPT0WU
G-402	NGHrUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoiwTWM2OD1yLkC0O\|g6KM7:TR?=	NXP4cmZTW0GQR1XS
DOK	M3HLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTnTWM2OD1yLkC0PVAzKM7:TR?=	M1jCSnNCVkeHUh?=
COR-L88	NV;sUHZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMES5NVIh\|ryP	MnXwV2FPT0WU
SKG-IIIa	NXnpR242T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkKxTWM2OD1yLkC0PVg3KM7:TR?=	NIrYRY1USU6JRWK=
AN3-CA	M2i3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjnOnRjUUN3ME2wMlA2KM7:TR?=	MWHTRW5ITVJ?
SW48	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMEWwN\|kh\|ryP	MmX4V2FPT0WU
YKG-1	M1z3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPQO3RmUUN3ME2wMlA2ODdzIN88US=>	NEGyVVZUSU6JRWK=
KYSE-150	NX\4e\|M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEWyN\|Uh\|ryP	MXjTRW5ITVJ?
HuO-3N1	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMEWyN\|ch\|ryP	MV\TRW5ITVJ?
LB1047-RCC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFX0XmhKSzVyPUCuNFUzQTZizszN	M4r4WXNCVkeHUh?=
NCI-H2030	NFy4RpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjjZlVKSzVyPUCuNFU1OTRizszN	NGP0UWpUSU6JRWK=
YH-13	NGHx[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XvUWlEPTB;MD6wOVczOiEQvF2=	MlX0V2FPT0WU
5637	M2nYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo[2TWM2OD1yLkC1O\|Qh\|ryP	MYjTRW5ITVJ?
LOXIMVI	M2XqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:3cllKSzVyPUCuNFU5PzJizszN	NUjxUXR3W0GQR1XS
GT3TKB	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjLc2dsUUN3ME2wMlA2QTR{IN88US=>	NWLMR5dKW0GQR1XS
TCCSUP	M{Die2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrPTWM2OD1yLkC1PVY1KM7:TR?=	NGC5Uo1USU6JRWK=
EPLC-272H	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[0TWM2OD1yLkC2NlA2KM7:TR?=	MnKzV2FPT0WU
LU-99A	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTvUIZVUUN3ME2wMlA3OjN5IN88US=>	MX3TRW5ITVJ?
NCI-H1755	NVr5Sm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{ToOWlEPTB;MD6wOlM1OSEQvF2=	MnnhV2FPT0WU
KM12	NFXYRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrDVHRKSzVyPUCuNFY{PDhizszN	M13u[XNCVkeHUh?=
SF295	M2W4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrSTWM2OD1yLkC2OFUzKM7:TR?=	MmnVV2FPT0WU
MZ2-MEL	M4DrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[3RmJzUUN3ME2wMlA3PTV\|IN88US=>	MUPTRW5ITVJ?
HEC-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4C2dGlEPTB;MD6wOlU5QCEQvF2=	NYLqdldkW0GQR1XS
SW684	NHn6VWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHjTWM2OD1yLkC2OVkyKM7:TR?=	NH;DNVdUSU6JRWK=
SF539	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwME[2PFEh\|ryP	NEfac5pUSU6JRWK=
GMS-10	NWHJPHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVT3bY5KUUN3ME2wMlA3Pjl7IN88US=>	M2Dx[nNCVkeHUh?=
MV-4-11	M4XJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFztVIhKSzVyPUCuNFY5ODNizszN	NUHtPGRiW0GQR1XS
HT-29	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfxcXpKSzVyPUCuNFY6OTlizszN	Mmi1V2FPT0WU
23132-87	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlr1TWM2OD1yLkC2PVUh\|ryP	NV\ndHBFW0GQR1XS
SW620	NITLZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzEd\|VKSzVyPUCuNFcxOjZizszN	MknHV2FPT0WU
HCC1806	Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWn2Ro83UUN3ME2wMlA4OTNzIN88US=>	M2X0TXNCVkeHUh?=
Hs-578-T	NWfWR2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzxTWM2OD1yLkC3NlA5KM7:TR?=	MW\TRW5ITVJ?
A2058	NXjycGI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NECxc\|NKSzVyPUCuNFczOjhizszN	Mmf5V2FPT0WU
MEL-HO	NFH1NJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVrkNlYyUUN3ME2wMlA4OjV3IN88US=>	NUXMbFFKW0GQR1XS
HCC2998	NIDkZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjsTWM2OD1yLkC3N\|Q4KM7:TR?=	NIKyTIpUSU6JRWK=
HuO9	M1jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXG1c4hjUUN3ME2wMlA4PTh7IN88US=>	NIPVb3pUSU6JRWK=
CAL-39	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUftTooyUUN3ME2wMlA4PzZ4IN88US=>	NULBToNFW0GQR1XS
M14	NXnTSoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEe5NVMh\|ryP	MYjTRW5ITVJ?
BFTC-909	M1T1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3HdFJKSzVyPUCuNFc6PjlizszN	NEXET2lUSU6JRWK=
TE-11	M2HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzrS41KSzVyPUCuNFc6QTZizszN	MUjTRW5ITVJ?
TGBC1TKB	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrGNGVKSzVyPUCuNFgxPDNizszN	NFfjeW1USU6JRWK=
L-363	NWT2OHBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TnRWlEPTB;MD6wPFIxPiEQvF2=	NWHMfGdTW0GQR1XS
A431	NEPsUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;TRWlEPTB;MD6wPFIyKM7:TR?=	M1:4ZnNCVkeHUh?=
MKN45	NWSwZXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMEiyNVkh\|ryP	M{\WdXNCVkeHUh?=
HT-1080	NH\XRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TMUGlEPTB;MD6wPFQ{QSEQvF2=	MljoV2FPT0WU
OVCAR-8	M3\GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMEi2NlIh\|ryP	NVHnWlRQW0GQR1XS
LCLC-97TM1	NWXhPHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fpW2lEPTB;MD6wPFczQCEQvF2=	NUixSZlKW0GQR1XS
M059J	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjmTWM2OD1yLkC5NFI4KM7:TR?=	MUXTRW5ITVJ?
SK-MEL-2	NXjBcJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrz[G5{UUN3ME2wMlA6ODZizszN	NHXaWoFUSU6JRWK=
TE-1	NILId2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXEO2FKSzVyPUCuNFkzODRizszN	NV2xRXFQW0GQR1XS
KYSE-180	NF7JendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjiV\|VKSzVyPUCuNFkzPjJizszN	MorpV2FPT0WU
D-247MG	M3;K[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfLbIViUUN3ME2wMlA6PDV3IN88US=>	MYrTRW5ITVJ?
8-MG-BA	M{PLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkf5TWM2OD1yLkC5OFczKM7:TR?=	MmjDV2FPT0WU
NCI-H1792	M1H1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWS2PJBmUUN3ME2wMlA6PjF6IN88US=>	MnHyV2FPT0WU
MCF7	M2PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEm2O\|ch\|ryP	NIjCVFJUSU6JRWK=
NCI-H2122	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE\wTFNKSzVyPUCuNFk4PDVizszN	M3zQUHNCVkeHUh?=
EFO-27	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMEm5PVch\|ryP	NWD3bGhKW0GQR1XS
LB2241-RCC	NH3pXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHMTWM2OD1yLkGwNFU1KM7:TR?=	M1LUWnNCVkeHUh?=
SN12C	NEjmR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1e1VGlEPTB;MD6xNFExPyEQvF2=	MXLTRW5ITVJ?
A498	M2HKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzGVpZsUUN3ME2wMlExOThizszN	NWTpepFPW0GQR1XS
PANC-03-27	M1LSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV61NY9FUUN3ME2wMlExOjh4IN88US=>	NYfRRpE{W0GQR1XS
NCI-H1581	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nvS2lEPTB;MD6xNFI6KM7:TR?=	NXzY[GY{W0GQR1XS
U-87-MG	NVL1[IFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH64coxKSzVyPUCuNVA{ODdizszN	MUTTRW5ITVJ?
G-401	M1npOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XXPWlEPTB;MD6xNFM2OyEQvF2=	NF;XfZVUSU6JRWK=
SiHa	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;POG1OUUN3ME2wMlExPDh4IN88US=>	MoTFV2FPT0WU
U251	NHPSOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMUC1NlUh\|ryP	M{\Kd3NCVkeHUh?=
MMAC-SF	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX3ZYhXUUN3ME2wMlExPTNzIN88US=>	M17QcHNCVkeHUh?=
BB65-RCC	M{\MeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnR[oRKSzVyPUCuNVA2PTRizszN	M3;Nb3NCVkeHUh?=
NKM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvFNWtWUUN3ME2wMlExPjZ4IN88US=>	MUXTRW5ITVJ?
HD-MY-Z	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX6zUFkxUUN3ME2wMlExQDd\|IN88US=>	M1ewVXNCVkeHUh?=
TGBC11TKB	M2DSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TnT2lEPTB;MD6xNFkxOyEQvF2=	Ml3xV2FPT0WU
COLO-679	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMUGyNVEh\|ryP	MYHTRW5ITVJ?
TE-8	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMUGyOlQh\|ryP	NX60[o9SW0GQR1XS
SK-MEL-28	M2HRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\3TWM2OD1yLkGxN\|IyKM7:TR?=	MkLUV2FPT0WU
SH-4	M2mwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUGzOVYh\|ryP	Mn3xV2FPT0WU
KALS-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjuTWM2OD1yLkGxN\|k{KM7:TR?=	M1\JdHNCVkeHUh?=
RKO	M13qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPXXoNvUUN3ME2wMlEyPzZ2IN88US=>	MXvTRW5ITVJ?
OMC-1	NFv0XZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvuTVBKSzVyPUCuNVE4QTdizszN	MnrWV2FPT0WU
BT-549	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMUG3PVkh\|ryP	M1PIenNCVkeHUh?=
NCI-H28	Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnKUJRKSzVyPUCuNVE5OTdizszN	M3rOPHNCVkeHUh?=
RXF393	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K2fmlEPTB;MD6xNVk5OiEQvF2=	MXzTRW5ITVJ?
COLO-829	NETKZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMUKwNFUh\|ryP	NFL0e5JUSU6JRWK=
HMV-II	M2TMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYO4SIVQUUN3ME2wMlEzODJizszN	NXzlOm9QW0GQR1XS
SW1990	NE[2RXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjDdYZKSzVyPUCuNVIyPTdizszN	M3GwfHNCVkeHUh?=
NCI-H1437	NFLUV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i5T2lEPTB;MD6xNlE2PyEQvF2=	MVzTRW5ITVJ?
SNB75	NVq0cVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfJSndKSzVyPUCuNVIyPjlizszN	M1PLRXNCVkeHUh?=
EW-3	MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\CTWM2OD1yLkGyOlYyKM7:TR?=	NVHXUok{W0GQR1XS
SAS	NGjObmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwMUK2PUDPxE1?	MnHsV2FPT0WU
NCI-H1666	NXvT[HRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4mxemlEPTB;MD6xNlc4PCEQvF2=	Mn7qV2FPT0WU
A375	NYfWSYRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWr5dm9tUUN3ME2wMlEzPzd6IN88US=>	NWnQVoFLW0GQR1XS
CAMA-1	NETQb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PadWlEPTB;MD6xNlkzPCEQvF2=	NHmz[VZUSU6JRWK=
HuP-T4	M2f0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHxd\|dTUUN3ME2wMlEzQTR\|IN88US=>	MnT2V2FPT0WU
NCI-H292	NHjn[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHFTWM2OD1yLkGzNVEh\|ryP	M1X0NHNCVkeHUh?=
PC-14	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTBwMUOyNVEh\|ryP	NFX4XGtUSU6JRWK=
BPH-1	NHzBfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMUO0NUDPxE1?	MmexV2FPT0WU
GAK	NELoUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\3VoJKSzVyPUCuNVM2PjdizszN	NXmwbYN7W0GQR1XS
VMRC-RCZ	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfwUmlKSzVyPUCuNVM4PjJizszN	NIDZN\|VUSU6JRWK=
SK-MEL-24	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvsTWM2OD1yLkGzPFch\|ryP	M4XjPHNCVkeHUh?=
LB831-BLC	NVLmT2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZc2lEPTB;MD6xN\|g5OyEQvF2=	NGXjVpNUSU6JRWK=
NCI-H2452	NHzKR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7rTWM2OD1yLkGzPVU3KM7:TR?=	NFL0TW1USU6JRWK=
RT-112	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nTOWlEPTB;MD6xOFA{PSEQvF2=	NV2wfYhIW0GQR1XS
GP5d	M3W5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFm4ZZpKSzVyPUCuNVQyODRizszN	M1;YVXNCVkeHUh?=
LC-2-ad	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M12zPWlEPTB;MD6xOFEzOSEQvF2=	Mn\BV2FPT0WU
MPP-89	MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zvbGlEPTB;MD6xOFEzPSEQvF2=	MkDOV2FPT0WU
NUGC-3	M2LkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMUS0O\|gh\|ryP	NUjZTYw2W0GQR1XS
GI-1	NX\hNWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfyTWM2OD1yLkG0OVU5KM7:TR?=	NWjBTmtJW0GQR1XS
HCC1419	M3G1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMUS1O\|Yh\|ryP	MmfEV2FPT0WU
SW1573	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TjS2lEPTB;MD6xOFc2QCEQvF2=	NUjUT5hpW0GQR1XS
NCI-H2347	NGDlPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmj4TWM2OD1yLkG0PFM6KM7:TR?=	NFHMUpNUSU6JRWK=
Mewo	NULNTVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMUS4PFkh\|ryP	MnrmV2FPT0WU
639-V	NGDxO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMUWwNVMh\|ryP	NGS4NIVUSU6JRWK=
AsPC-1	NFG4R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHToT2tKSzVyPUCuNVUzOjVizszN	NXLXUZFFW0GQR1XS
NCI-H1648	NGLjU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlS5TWM2OD1yLkG1NlMzKM7:TR?=	MXjTRW5ITVJ?
786-0	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfIXHF1UUN3ME2wMlE2OzhzIN88US=>	NYjFeY43W0GQR1XS
ETK-1	M1fjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMUW5JO69VQ>?	MYPTRW5ITVJ?
BxPC-3	NF[2OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HXTWlEPTB;MD6xOVk3PiEQvF2=	MWnTRW5ITVJ?
CAL-62	NWW2UIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3CTWM2OD1yLkG2NVY6KM7:TR?=	M1\PVHNCVkeHUh?=
HCC1937	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjWS4FXUUN3ME2wMlE3Ojd3IN88US=>	MlLDV2FPT0WU
NCI-H1299	NXPNUotZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;iOXBKSzVyPUCuNVYzQDVizszN	NEDKfZBUSU6JRWK=
SW1088	NGLoU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMU[0NVMh\|ryP	NF\NPXhUSU6JRWK=
FTC-133	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwMU[1OEDPxE1?	MY\TRW5ITVJ?
OC-314	NHq2WmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMU[2PUDPxE1?	MU\TRW5ITVJ?
SCC-9	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPkTWM2OD1yLkG2O\|E3KM7:TR?=	Mn;MV2FPT0WU
HT-1376	M3PGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMU[5N\|Yh\|ryP	MYjTRW5ITVJ?
U-2-OS	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULQPWk2UUN3ME2wMlE4OTd\|IN88US=>	Mme4V2FPT0WU
COLO-824	M{fhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3mTWM2OD1yLkG3Nlk1KM7:TR?=	NVfNfXMyW0GQR1XS
BB30-HNC	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHhV25KSzVyPUCuNVc{OyEQvF2=	Mn\YV2FPT0WU
NCI-H2087	NYXVXIJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwMUezOlgh\|ryP	MV3TRW5ITVJ?
NCI-H2170	M2X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\VTWM2OD1yLkG3OVM3KM7:TR?=	M1;GT3NCVkeHUh?=
SK-OV-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPV[mNKSzVyPUCuNVc2PzFizszN	NYPmfmJvW0GQR1XS
MZ7-mel	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXRcW1FUUN3ME2wMlE4PjR7IN88US=>	M{PCcXNCVkeHUh?=
NCI-H650	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMUe2PFIh\|ryP	Mm\JV2FPT0WU
KOSC-2	M2PvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jWRWlEPTB;MD6xO\|c{PCEQvF2=	M4jnbXNCVkeHUh?=
SCC-4	NXPiSW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mni5TWM2OD1yLkG3O\|c4KM7:TR?=	MlnEV2FPT0WU
MDA-MB-157	NF;RVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zJVGlEPTB;MD6xPFA5OiEQvF2=	Mn;CV2FPT0WU
KYSE-520	NYTvNYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMUiyJO69VQ>?	MlHSV2FPT0WU
LK-2	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMUizNFMh\|ryP	MkPSV2FPT0WU
KNS-81-FD	NILuTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fvOWlEPTB;MD6xPFM6PCEQvF2=	M1LPcXNCVkeHUh?=
IGROV-1	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M362XmlEPTB;MD6xPFQ1OyEQvF2=	MUnTRW5ITVJ?
DEL	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3K2W2lEPTB;MD6xPFQ2KM7:TR?=	NFW0OopUSU6JRWK=
NCI-H1395	NF7EXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXPfmt6UUN3ME2wMlE5Pjh{IN88US=>	MXzTRW5ITVJ?
JEG-3	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwMUi3NFUh\|ryP	MmXrV2FPT0WU
BCPAP	NWfaRYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH74T2pKSzVyPUCuNVg5PzJizszN	NUT5bFFSW0GQR1XS
CAL-27	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfudoVKUUN3ME2wMlE6ODJ{IN88US=>	MkTPV2FPT0WU
RD	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMUmxNVMh\|ryP	Ml[zV2FPT0WU
RVH-421	Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPVXJlKSzVyPUCuNVkyOTZizszN	NWDR[G5sW0GQR1XS
Capan-2	NYnFbJR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMUmyOVYh\|ryP	MYXTRW5ITVJ?
COLO-680N	M3;kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMUmzOlQh\|ryP	MoLrV2FPT0WU
NCI-H1650	NYqwfHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:3bmlEPTB;MD6yNFA2PyEQvF2=	NUHVR4Z2W0GQR1XS
SBC-5	NWnMPHZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2X2OmlEPTB;MD6yNFEyQCEQvF2=	NVP4U4tUW0GQR1XS
U031	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMkC1OFch\|ryP	M2XFSHNCVkeHUh?=
S-117	MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrHbINNUUN3ME2wMlIxPTZ2IN88US=>	NYfhV4tGW0GQR1XS
DoTc2-4510	M2D0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwMkC3Olkh\|ryP	NGrFNZFUSU6JRWK=
AM-38	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\jfWlEPTB;MD6yNFg1QCEQvF2=	MXPTRW5ITVJ?
A172	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vUN2lEPTB;MD6yNVAzOiEQvF2=	MnjXV2FPT0WU
HPAF-II	NGL0bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojVTWM2OD1yLkKxNlY1KM7:TR?=	MYHTRW5ITVJ?
769-P	M1foPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMkGyPEDPxE1?	NULS[2xjW0GQR1XS
MFE-280	MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvDe3VDUUN3ME2wMlIyOjl6IN88US=>	NFLjSWRUSU6JRWK=
TE-9	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMkG3PFYh\|ryP	NET3T5JUSU6JRWK=
C2BBe1	NGn4O2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TtfGlEPTB;MD6yNlE6KM7:TR?=	NYXtOZBnW0GQR1XS
EoL-1-cell	NF63NJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMkKyNFMh\|ryP	MnrQV2FPT0WU
G-361	NVrqflJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWX1VXlbUUN3ME2wMlIzPjh{IN88US=>	MXjTRW5ITVJ?
KYSE-270	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMkOwPFQh\|ryP	MVTTRW5ITVJ?
TK10	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;nPXhKSzVyPUCuNlMyOTdizszN	NEjJXlFUSU6JRWK=
ML-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLjdJFTUUN3ME2wMlI{OTF7IN88US=>	M1fESXNCVkeHUh?=
MHH-ES-1	M37zcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoL5TWM2OD1yLkKzOlgyKM7:TR?=	NEXEfnlUSU6JRWK=
BHY	NWP0TVBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTBwMkO2PVEh\|ryP	M2PHe3NCVkeHUh?=
LS-513	M{jI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[2PGlEPTB;MD6yN\|k3OSEQvF2=	M33OUHNCVkeHUh?=
COLO-678	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\TOY5GUUN3ME2wMlI1ODR2IN88US=>	NFSxXJJUSU6JRWK=
NCI-H747	NXzYeo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGexZWlKSzVyPUCuNlQyPjlizszN	Mo\iV2FPT0WU
K5	M{LWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7RTWM2OD1yLkK0N\|gh\|ryP	MlW5V2FPT0WU
OS-RC-2	M3zwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;HTWM2OD1yLkK0OVA6KM7:TR?=	Ml;yV2FPT0WU
KINGS-1	M1nOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS3TWM2OD1yLkK0OVI6KM7:TR?=	MWrTRW5ITVJ?
SCC-25	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\zTZNWUUN3ME2wMlI1PTZ\|IN88US=>	NGPjTVdUSU6JRWK=
CAPAN-1	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fpXWlEPTB;MD6yOFc5OyEQvF2=	MYTTRW5ITVJ?
ESS-1	MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHMU5h4UUN3ME2wMlI1QDB3IN88US=>	MorEV2FPT0WU
TE-6	NG\OeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2X2XGlEPTB;MD6yOVc2KM7:TR?=	NUXGfmFVW0GQR1XS
LB2518-MEL	NHfDNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMkW3O\|ch\|ryP	NYDId\|V[W0GQR1XS
COLO-800	NUfyXJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXLSIlKSzVyPUCuNlU5OTJizszN	Mo\kV2FPT0WU
LU-134-A	M3XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmT4TWM2OD1yLkK2NVM3KM7:TR?=	NH;xeYtUSU6JRWK=
NCI-H1155	NHrmRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlr6TWM2OD1yLkK2NVYzKM7:TR?=	MljFV2FPT0WU
MFM-223	NGH4VHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfiZmtKSzVyPUCuNlY{PjNizszN	MV;TRW5ITVJ?
HTC-C3	M4HBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMk[1NFYh\|ryP	M1znV3NCVkeHUh?=
HCT-116	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMk[1PVkh\|ryP	NHrieYFUSU6JRWK=
Ca-Ski	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3n3cmlEPTB;MD6yOlY4QCEQvF2=	NWf3Sog6W0GQR1XS
SBC-1	NWPxbmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PkcWlEPTB;MD6yOlc1OiEQvF2=	MlzLV2FPT0WU
NB69	M1:4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\5TmtQUUN3ME2wMlI4ODh5IN88US=>	NVLBVoFWW0GQR1XS
J82	NGHX[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvYTWM2OD1yLkK3NlY2KM7:TR?=	MnrpV2FPT0WU
U-118-MG	M{Cz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmiyTWM2OD1yLkK3OVc6KM7:TR?=	MVHTRW5ITVJ?
NCI-H1355	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMkiwO\|Qh\|ryP	M{X1bHNCVkeHUh?=
NCI-H1048	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkL2TWM2OD1yLkK4PVU3KM7:TR?=	M17Zd3NCVkeHUh?=
SW954	NGjiTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PnNmlEPTB;MD6yPVIzPyEQvF2=	MXXTRW5ITVJ?
NMC-G1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLBbHFEUUN3ME2wMlI6Ojd5IN88US=>	NGHXcGpUSU6JRWK=
SW1710	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHtcGRKSzVyPUCuNlk1QTRizszN	NUO2ZVhDW0GQR1XS
KY821	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\BZWVKSzVyPUCuNlk5PzJizszN	M3W3R3NCVkeHUh?=
HCC38	NFfyRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;GRWlEPTB;MD6zNFA4QCEQvF2=	M3XsZ3NCVkeHUh?=
NCI-SNU-5	NGnDPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvyTWM2OD1yLkOwOVQh\|ryP	NFzub21USU6JRWK=
ES8	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnvW4lKSzVyPUCuN\|A4QDRizszN	M2DleXNCVkeHUh?=
COLO-792	NFK4[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\i[2VCUUN3ME2wMlMyOjVzIN88US=>	MofIV2FPT0WU
BFTC-905	M4\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmP6TWM2OD1yLkOxOVIyKM7:TR?=	M3XVUXNCVkeHUh?=
ChaGo-K-1	NFj2W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:0Ro4{UUN3ME2wMlMyPzF3IN88US=>	NVGwOJg6W0GQR1XS
Daoy	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjwfmlKSzVyPUCuN\|E4OjNizszN	MV;TRW5ITVJ?
SJSA-1	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnzNZNxUUN3ME2wMlMyQDR5IN88US=>	MojiV2FPT0WU
KNS-62	NIjNc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjUPZRKSzVyPUCuN\|IxQDhizszN	MV7TRW5ITVJ?
CAKI-1	MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXmTWM2OD1yLkOyNVEyKM7:TR?=	NFznNIhUSU6JRWK=
UACC-62	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwM{KyNlch\|ryP	Mn;UV2FPT0WU
HuCCT1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjqTWM2OD1yLkOyNlg{KM7:TR?=	M2KycHNCVkeHUh?=
CTB-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPaNHRKSzVyPUCuN\|I4PTNizszN	NG\CdotUSU6JRWK=
NTERA-S-cl-D1	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjaU2pKSzVyPUCuN\|I5OzZizszN	MoTkV2FPT0WU
T-24	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwM{OxOVkh\|ryP	NHSzTItUSU6JRWK=
KYSE-70	NX72R3dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\5fXBKSzVyPUCuN\|MzQDNizszN	MmTsV2FPT0WU
SW626	NUnxfoIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13nNmlEPTB;MD6zN\|U{OiEQvF2=	MkDJV2FPT0WU
LB996-RCC	NGPMcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH5S4lKSzVyPUCuN\|M3OTlizszN	M136cHNCVkeHUh?=
DMS-273	NXTxclM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTpcZV1UUN3ME2wMlM{QTF4IN88US=>	NWrkWoNoW0GQR1XS
SW1783	NEPMcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwM{O5PVch\|ryP	M{XORnNCVkeHUh?=
KU812	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfJ[nk4UUN3ME2wMlM1ODN6IN88US=>	MUXTRW5ITVJ?
HSC-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTBwM{SwOVMh\|ryP	Ml;aV2FPT0WU
A3-KAW	M2\Ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\HWG9uUUN3ME2wMlM1OTZ{IN88US=>	NYXPc5FHW0GQR1XS
COLO-684	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTWfnlQUUN3ME2wMlM1PTBzIN88US=>	Mn3YV2FPT0WU
NCI-H2405	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFOyUVRKSzVyPUCuN\|Q3OzFizszN	M1flVHNCVkeHUh?=
NCI-H2228	M3jjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPTTIIyUUN3ME2wMlM2OzV5IN88US=>	Mnf6V2FPT0WU
NB13	NYS2WHFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfLXoxOUUN3ME2wMlM3QDJ7IN88US=>	MYXTRW5ITVJ?
no-11	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlO2TWM2OD1yLkO2PVUh\|ryP	MWjTRW5ITVJ?
DK-MG	NV3aU\|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NED4XJlKSzVyPUCuN\|cyQDhizszN	Ml\NV2FPT0WU
NBsusSR	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk[wTWM2OD1yLkO3Nlg2KM7:TR?=	M1jVUnNCVkeHUh?=
KP-N-YS	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\6TWM2OD1yLkO3OFY{KM7:TR?=	MUPTRW5ITVJ?
CFPAC-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwM{e1NVgh\|ryP	NHe3ZoVUSU6JRWK=
KARPAS-45	NILSXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwM{e4OlIh\|ryP	NFHyeolUSU6JRWK=
NCI-H1793	NVP0VldnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwM{i1NUDPxE1?	M1[0NXNCVkeHUh?=
HCE-T	NWTIXllHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zhOmlEPTB;MD6zPFYxOyEQvF2=	MWLTRW5ITVJ?
NCI-H520	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXZTIU{UUN3ME2wMlM5PzB\|IN88US=>	NIizNWlUSU6JRWK=
HCC2157	NWfyb3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\o[IdKSzVyPUCuN\|g4QDFizszN	MWfTRW5ITVJ?
EW-18	NEDlcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\GcWlEPTB;MD6zPFk1OSEQvF2=	NVnoOIJJW0GQR1XS
RO82-W-1	M3rTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nKUmlEPTB;MD6zPVY6QSEQvF2=	NHzQSnJUSU6JRWK=
HuP-T3	NFPz[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvkTWM2OD1yLkSwNVQ{KM7:TR?=	NEWxfY1USU6JRWK=
PANC-10-05	NHTDSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j1UmlEPTB;MD60NVE4KM7:TR?=	MljJV2FPT0WU
NCI-H1703	NFTCfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrUeZdSUUN3ME2wMlQyPDR4IN88US=>	M2rOPXNCVkeHUh?=
TE-10	NE\xTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7SRVRTUUN3ME2wMlQyPDR5IN88US=>	NWWyWoNFW0GQR1XS
HOS	NVX2O2F3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrCTWM2OD1yLkSxOlgzKM7:TR?=	MojJV2FPT0WU
LN-405	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvtTWM2OD1yLkSxOlg4KM7:TR?=	MULTRW5ITVJ?
A427	M17KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HxbWlEPTB;MD60NVk5OSEQvF2=	M2qzTnNCVkeHUh?=
CAL-12T	NUDnfYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknITWM2OD1yLkSyO\|gh\|ryP	NHfXd3hUSU6JRWK=
SW756	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwNESxPFMh\|ryP	NUDocnY4W0GQR1XS
YAPC	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPpTWM2OD1yLkS1NFgh\|ryP	M3X0T3NCVkeHUh?=
GOTO	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNEWxOkDPxE1?	MVnTRW5ITVJ?
C3A	NXX0dnhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;LSIp{UUN3ME2wMlQ2PDN5IN88US=>	NVfDcnhYW0GQR1XS
UM-UC-3	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwNEW0O{DPxE1?	NXf6UFdWW0GQR1XS
NCI-H1573	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwNEW1Olkh\|ryP	Mn\3V2FPT0WU
LS-411N	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfFeYN[UUN3ME2wMlQ3PTJ5IN88US=>	MWrTRW5ITVJ?
COR-L23	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f0W2lEPTB;MD60Olc3PCEQvF2=	NXPqeld5W0GQR1XS
HCE-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnxUY9HUUN3ME2wMlQ4PDR4IN88US=>	M1mzN3NCVkeHUh?=
NCI-H2291	NF[0WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwNEe4PVYh\|ryP	MVjTRW5ITVJ?
A101D	NYCyNIVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwNEiwOVMh\|ryP	NWD4c2hZW0GQR1XS
HT-3	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v3RWlEPTB;MD60PFIyPyEQvF2=	MVHTRW5ITVJ?
HOP-62	NYnEPGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jueGlEPTB;MD60PVg3PSEQvF2=	MX\TRW5ITVJ?
PC-3	NVPXVVVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrjb5BoUUN3ME2wMlUyPTB5IN88US=>	MUTTRW5ITVJ?
CTV-1	NVHhPXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTqTWM2OD1yLkWyOlY6KM7:TR?=	NWHMZ4FGW0GQR1XS
PANC-08-13	M33VdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DOe2lEPTB;MD61N\|E4PyEQvF2=	MmfDV2FPT0WU
CAL-120	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwNUOzPVkh\|ryP	MXjTRW5ITVJ?
UMC-11	NXTYPIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXZTHFKSzVyPUCuOVUzOzRizszN	NFrt[mFUSU6JRWK=
MSTO-211H	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfvd3pKSzVyPUCuOVU4PjJizszN	MWLTRW5ITVJ?
NCI-H2126	NUTibJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS0VXFUUUN3ME2wMlU3QDF3IN88US=>	MYDTRW5ITVJ?
SNU-C2B	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHG1U4JKSzVyPUCuOVc6PzdizszN	MX7TRW5ITVJ?
DBTRG-05MG	NF7KbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkSzTWM2OD1yLkW4NFU{KM7:TR?=	MWXTRW5ITVJ?
MKN1	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNUi3PFMh\|ryP	MXzTRW5ITVJ?
ES3	NIXncVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DBTmlEPTB;MD61PVEzPCEQvF2=	M1\wfXNCVkeHUh?=
OVCAR-3	NGWxN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\qSJQ{UUN3ME2wMlU6OzRzIN88US=>	NXvXd4JEW0GQR1XS
ACHN	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW4S49RUUN3ME2wMlYxPTZ7IN88US=>	MkPFV2FPT0WU
SW872	NEH0emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrJTWM2OD1yLk[wO\|Y{KM7:TR?=	MXzTRW5ITVJ?
CP66-MEL	M4DPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDxTWM2OD1yLk[wPVY6KM7:TR?=	MlrYV2FPT0WU
NCI-H661	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVf0fHY{UUN3ME2wMlYyOTB2IN88US=>	MWrTRW5ITVJ?
UACC-893	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XiZ2lEPTB;MD62N\|Y5OSEQvF2=	NECz[WtUSU6JRWK=
JVM-3	NU\0WpVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwNkO4NFQh\|ryP	M1fOOnNCVkeHUh?=
SF268	NUeyVFI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwNkSzOFkh\|ryP	MYPTRW5ITVJ?
OCI-AML2	M3W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHDOHdKSzVyPUCuOlU{QTdizszN	MnPuV2FPT0WU
RPMI-8226	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\VN2lEPTB;MD62OlMzOyEQvF2=	NEPxXXJUSU6JRWK=
MKN28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK2e\|Y1UUN3ME2wMlY3PjJ2IN88US=>	M{O5d3NCVkeHUh?=
MDA-MB-453	M2\wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moq4TWM2OD1yLk[3NVgh\|ryP	NEDtWVRUSU6JRWK=
BV-173	M2rNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwNki2O\|kh\|ryP	M3ztPXNCVkeHUh?=
NCI-H358	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNki3NlYh\|ryP	MWnTRW5ITVJ?
NCI-H1651	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3FV5d4UUN3ME2wMlch\|ryP	NHnncXRUSU6JRWK=
MDA-MB-415	NV;rWoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy4cYZZUUN3ME2wMlcxQDJ7IN88US=>	MUTTRW5ITVJ?
8305C	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[5cZVKSzVyPUCuO\|I1QThizszN	M4LlcnNCVkeHUh?=
EFM-19	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moq0TWM2OD1yLkezOlcyKM7:TR?=	MkHLV2FPT0WU
RERF-LC-MS	M3LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7FV244UUN3ME2wMlc1PjF\|IN88US=>	NVfyTWtwW0GQR1XS
A388	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLV[G45UUN3ME2wMlc3PDZ5IN88US=>	M2HSbHNCVkeHUh?=
GI-ME-N	M2mzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2H4OWlEPTB;MD63O\|I{PSEQvF2=	NWK0VIZFW0GQR1XS
IGR-1	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nZZWlEPTB;MD63PVA1OyEQvF2=	Ml;MV2FPT0WU
LNCaP-Clone-FGC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWf5SVA3UUN3ME2wMlgxODB2IN88US=>	MXPTRW5ITVJ?
SK-MEL-3	NHnnXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwOEG1NFgh\|ryP	MnHwV2FPT0WU
UACC-257	NHy0NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDmTWM2OD1yLkiyNlMyKM7:TR?=	NXTIPVRZW0GQR1XS
OE33	MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrKN3ZKSzVyPUCuPFUyODFizszN	M1rSWnNCVkeHUh?=
QIMR-WIL	NULmPW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwOEWxOFEh\|ryP	NXLreZM{W0GQR1XS
NCI-H2009	M3rHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1npZ2lEPTB;MD64OVMyOSEQvF2=	NIXzfXNUSU6JRWK=
NCI-H522	M3m2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHLfXp2UUN3ME2wMlg4Pzh\|IN88US=>	Ml\CV2FPT0WU
Saos-2	NF\xOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDuTWM2OD1yLki3PFcyKM7:TR?=	M1r4OXNCVkeHUh?=
NB17	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXCWY5tUUN3ME2wMlg5ODJ3IN88US=>	NETMeZlUSU6JRWK=
D-392MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwOEmzOVYh\|ryP	NFqyUINUSU6JRWK=
SHP-77	NHzYVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwOUC0PFUh\|ryP	NIL5O49USU6JRWK=
SK-MEL-30	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvkTo83UUN3ME2wMlkyOTh3IN88US=>	NGrPcZpUSU6JRWK=
GCIY	NHLqdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfqRnJKSzVyPUCuPVE5PDNizszN	MojBV2FPT0WU
HCC70	NUPlbnZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFqyNWxKSzVyPUCuPVIxPTlizszN	MoDIV2FPT0WU
LU-65	NXq0Rot5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jlUGlEPTB;MD65NlU6OSEQvF2=	NEHRXI1USU6JRWK=
NCI-H1563	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTpXWdKSzVyPUCuPVQ5PjVizszN	M37WSnNCVkeHUh?=
KURAMOCHI	NWnOeHV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Hhd2lEPTB;MD65OVE6OiEQvF2=	M2LreHNCVkeHUh?=
PA-1	M{fjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwOUW0NlQh\|ryP	MXLTRW5ITVJ?
NOS-1	NWeweJh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\PdJd2UUN3ME2wMlk4PDh7IN88US=>	MWLTRW5ITVJ?
NCI-H69	M1v3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwOUe2N\|Qh\|ryP	MoPYV2FPT0WU
KYSE-450	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXP1OVdZUUN3ME2wMlk5PjJ4IN88US=>	NWjxNmh5W0GQR1XS
8505C	NWjlR4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;PZVlIUUN3ME2wMlk6QTh{IN88US=>	MonlV2FPT0WU
TGBC24TKB	NHvYO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO2TWM2OD1zLkCwNFg1KM7:TR?=	MmLMV2FPT0WU
PFSK-1	NEjoUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwMEG0Nlgh\|ryP	NHTWeFlUSU6JRWK=
EKVX	NYLjUlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7tSWFKSzVyPUGuNFMyOjFizszN	M1TLTnNCVkeHUh?=
RCM-1	NVTjNZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\STWM2OD1zLkC1OVA4KM7:TR?=	NEPafppUSU6JRWK=
SW900	NGf3R4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwMEe4N{DPxE1?	NFPJXZhUSU6JRWK=
D-542MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPMTWM2OD1zLkC3PFU2KM7:TR?=	MX\TRW5ITVJ?
SK-PN-DW	NWewTpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW4TWM2OD1zLkGwNFU3KM7:TR?=	MoPwV2FPT0WU
NCI-H727	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDPTWM2OD1zLkGwNVU1KM7:TR?=	Mlq5V2FPT0WU
SW837	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7rTWM2OD1zLkGwPVU1KM7:TR?=	MorJV2FPT0WU
BT-20	NX\wbFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrVTWM2OD1zLkGxNlA1KM7:TR?=	M3n2SnNCVkeHUh?=
RH-18	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{H0cmlEPTB;MT6xN\|ExOyEQvF2=	MmnuV2FPT0WU
TE-12	NGjIXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7Yd5dXUUN3ME2xMlE{OzN\|IN88US=>	MYfTRW5ITVJ?
NB10	NXW0Um4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLjTWM2OD1zLkGzN\|Q1KM7:TR?=	MoX3V2FPT0WU
AU565	NH7LcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTFwMUW5O\|Mh\|ryP	NEXnTI5USU6JRWK=
OAW-42	NUm4TmZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPTTWM2OD1zLkG4N\|A3KM7:TR?=	M2nFUHNCVkeHUh?=
DJM-1	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTFwMUm4PFEh\|ryP	NV2wUlZZW0GQR1XS
HH	M3zDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFwMkO4N\|Eh\|ryP	NUDjfVJ2W0GQR1XS
LAMA-84	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHq[WZKSzVyPUGuNlc{QTRizszN	Mkf0V2FPT0WU
KNS-42	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M370NGlEPTB;MT6zNFI6PiEQvF2=	M2GwUnNCVkeHUh?=
NCI-H2052	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTFwM{C1NFch\|ryP	M{jT[HNCVkeHUh?=
MLMA	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrWVJBsUUN3ME2xMlMzPDB5IN88US=>	MUTTRW5ITVJ?
NB12	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHieGp{UUN3ME2xMlM2PjN4IN88US=>	MUnTRW5ITVJ?
NCI-H1838	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHyyUZBKSzVyPUGuN\|Y{ODZizszN	NIXFPJVUSU6JRWK=
NCI-H526	M1fOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f0[GlEPTB;MT6zO\|g2OyEQvF2=	NVfmV3o6W0GQR1XS
LS-123	NHWwToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzIZlBKSzVyPUGuN\|kxQTRizszN	M3rDVHNCVkeHUh?=
HDLM-2	MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwM{myO\|Eh\|ryP	MnjzV2FPT0WU
MC-IXC	NV\HdWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1WybGlEPTB;MT60NlM4OSEQvF2=	MVLTRW5ITVJ?
HCT-15	M3Sw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTZNZJKSzVyPUGuOFMxPjhizszN	NWm3Z4VOW0GQR1XS
NCI-H596	NXXwcIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\rVFdKSzVyPUGuOFUxPjFizszN	NFHUeFlUSU6JRWK=
ZR-75-30	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnuTWM2OD1zLkS3NFgzKM7:TR?=	NXTsTpg2W0GQR1XS
A704	NUPSXlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXi2OXRqUUN3ME2xMlY3PTZ\|IN88US=>	M{f3fnNCVkeHUh?=
OVCAR-4	NETP[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PMbmlEPTB;MT62PVYxPyEQvF2=	MnjvV2FPT0WU
SW1417	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwN{K4OFkh\|ryP	MUHTRW5ITVJ?
CAS-1	M3;0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XLOmlEPTB;MT63N\|k{PiEQvF2=	NFPibWdUSU6JRWK=
IST-SL1	M{jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTFwN{m3OVkh\|ryP	MXrTRW5ITVJ?
A253	M1nMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHtRoZKSzVyPUGuPFIzOzlizszN	MoDUV2FPT0WU
EW-16	NHTEcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH6Z4ZPUUN3ME2xMlgzQDd3IN88US=>	NF63eVdUSU6JRWK=
SK-NEP-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFwOE[5PFgh\|ryP	NIXUXHJUSU6JRWK=
NCI-H226	NG\WT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O0SGlEPTB;MT64PVM2QSEQvF2=	M13acXNCVkeHUh?=
HOP-92	NE\zOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\1TWM2OD1zLkm2NFk6KM7:TR?=	NInxdWxUSU6JRWK=
NCI-H441	MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTHUmtZUUN3ME2yMlAzOzN5IN88US=>	M{Dh[XNCVkeHUh?=
LU-139	NX:3fJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJwMEOxNVQh\|ryP	NVXFRXpkW0GQR1XS
SJRH30	NHjuN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXy3dIY1UUN3ME2yMlA1OjV\|IN88US=>	M2fhSHNCVkeHUh?=
MG-63	NEnYV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELaZm1KSzVyPUKuNVQyOTFizszN	MWHTRW5ITVJ?
NH-12	M37SPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTJwMUWwNFYh\|ryP	M2rmXHNCVkeHUh?=
NB7	M33xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJwMUm2O\|Mh\|ryP	MV7TRW5ITVJ?
LB771-HNC	NFLlfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTJwMkC1PVUh\|ryP	NHzaVFFUSU6JRWK=
HCC1569	NGHnPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrQZoJWUUN3ME2yMlI1PTh\|IN88US=>	M3zXRnNCVkeHUh?=
D-283MED	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkW4TWM2OD1{LkK0O\|gzKM7:TR?=	NECxTHhUSU6JRWK=
J-RT3-T3-5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HtZmlEPTB;Mj6yOVM2OSEQvF2=	M3fwb3NCVkeHUh?=
ATN-1	NF;qZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEWzPHdKSzVyPUKuN\|MxQDJizszN	MXzTRW5ITVJ?
HCC1954	NFzIWGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTtTWM2OD1{LkO0OFA5KM7:TR?=	NUX5NGtwW0GQR1XS
SCC-15	M2rmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW4NXlKSzVyPUKuN\|k{OTJizszN	M3z0PHNCVkeHUh?=
COLO-668	M{nvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJwNEOyJO69VQ>?	NXfIcWZ3W0GQR1XS
LB373-MEL-D	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv1TWM2OD1{LkW0Olc4KM7:TR?=	Ml\nV2FPT0WU
no-10	NYHHeJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S5b2lEPTB;Mj61OFk1PyEQvF2=	Mn7IV2FPT0WU
HT-1197	M3nLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvkSG1KSzVyPUKuOlMyQDhizszN	MULTRW5ITVJ?
DU-145	M3XUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfITmRMUUN3ME2yMlc6OTZ{IN88US=>	M3LWOHNCVkeHUh?=
SK-N-AS	NUfhW4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWOyfoxYUUN3ME2yMlg1Pjl{IN88US=>	MY\TRW5ITVJ?
MOLT-4	NUD0dJA4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJwOEWzNlIh\|ryP	NGjPV3pUSU6JRWK=
EW-22	M4\lRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\rO3JKSzVyPUKuPVI5PDFizszN	M37XUHNCVkeHUh?=
DB	M2GyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWKyT5o5UUN3ME2yMlk4PzV7IN88US=>	NF\oSWlUSU6JRWK=
HL-60	NVy3VlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTNwMESzO\|Yh\|ryP	M1TsO3NCVkeHUh?=
SK-N-DZ	M2nROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HJVGlEPTB;Mz6wOVA4PSEQvF2=	NHy4dldUSU6JRWK=
NY	M2H6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4q4eGlEPTB;Mz6wPFU1OiEQvF2=	MlPXV2FPT0WU
T47D	NGDyT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTNwMUC1OVgh\|ryP	NXLu[\|NsW0GQR1XS
NCI-H2029	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\NTWM2OD1\|LkKyOFc4KM7:TR?=	MmHlV2FPT0WU
KARPAS-299	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13hOGlEPTB;Mz6yOlAzPyEQvF2=	MVLTRW5ITVJ?
KM-H2	MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNwM{C2PEDPxE1?	NVnsVItsW0GQR1XS
CHP-134	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTNwNEezPUDPxE1?	MXHTRW5ITVJ?
22RV1	NIXhd\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXKTWM2OD1\|LkS5NVY5KM7:TR?=	NFzFOXFUSU6JRWK=
NB5	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rUdWlEPTB;Mz61NFY5QSEQvF2=	MY\TRW5ITVJ?
CW-2	NIPQO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m3b2lEPTB;Mz61OVMyPCEQvF2=	MYjTRW5ITVJ?
EFO-21	NWXJb\|M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XoRWlEPTB;Mz61Olk1KM7:TR?=	MVPTRW5ITVJ?
HuH-7	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULqUpY6UUN3ME2zMlU5PDF2IN88US=>	M4XlPXNCVkeHUh?=
ALL-PO	MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4T0S2lEPTB;Mz62NlM{PSEQvF2=	MXTTRW5ITVJ?
EM-2	NFj4N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL6TWM2OD1\|Lk[5NFEyKM7:TR?=	M1TxSnNCVkeHUh?=
KLE	NYjpUFRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf0TWM2OD1\|LkezNFI6KM7:TR?=	MYTTRW5ITVJ?
NEC8	M33MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTNwOUG4NFgh\|ryP	MmP2V2FPT0WU
KP-N-YN	M{f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvXTWM2OD1\|LkmzOFc3KM7:TR?=	NWKzU4RFW0GQR1XS
SK-MEL-1	M{DLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEKzfFdKSzVyPUSuNFM2OThizszN	MWDTRW5ITVJ?
CAL-54	MoTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTRwMEW5NUDPxE1?	M2\TPXNCVkeHUh?=
MS-1	NHO3b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnFboN2UUN3ME20MlE3OTV3IN88US=>	M4K3PHNCVkeHUh?=
NCI-H209	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTRwMkm5PVkh\|ryP	NHvoTJJUSU6JRWK=
NOMO-1	NGDSVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTkRmNKSzVyPUSuN\|IyOzFizszN	M1\VdnNCVkeHUh?=
RPMI-2650	NGTFSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTRwM{[zNlch\|ryP	NWPNPXhbW0GQR1XS
NCI-H810	M1PZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTRwM{m3N\|Yh\|ryP	MnnvV2FPT0WU
Ca9-22	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFSweFdKSzVyPUSuOFU3QTFizszN	NWf2dpNUW0GQR1XS
ES4	NYe5fIRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL5[YFnUUN3ME20MlQ4ODl3IN88US=>	M3X5eXNCVkeHUh?=
ES6	M3:zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\we2lEPTB;ND60PVY2PyEQvF2=	M4[0PHNCVkeHUh?=
DMS-114	M3LVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTtb2kzUUN3ME20MlU1PjlzIN88US=>	NVq4b2V7W0GQR1XS
ONS-76	NHjpUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjSOWRPUUN3ME20MlU4QTVizszN	NF;DbGlUSU6JRWK=
K-562	M4Trc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTRwN{O4NVQh\|ryP	MXzTRW5ITVJ?
MHH-NB-11	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XLXWlEPTB;ND63OVQ3OSEQvF2=	NI\ZZpRUSU6JRWK=
Calu-3	NEWx[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\nV4NKSzVyPUSuO\|g2PDhizszN	NEPSN\|BUSU6JRWK=
HT55	NHfUXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTRwOES1OFUh\|ryP	NGG2TFNUSU6JRWK=
SK-N-FI	M3q2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfXVpFKSzVyPUSuPFUxODlizszN	MmrSV2FPT0WU
ES1	NF7xTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmm2TWM2OD12Lki2NFU4KM7:TR?=	MVTTRW5ITVJ?
SF126	NFr2bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLmTWM2OD12LkmzNVg1KM7:TR?=	NFTtdYlUSU6JRWK=
ES5	MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rt[mlEPTB;NT6xNlQzPyEQvF2=	M{faenNCVkeHUh?=
LoVo	M2XYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPETWM2OD13LkG1PFcyKM7:TR?=	NGO5V5JUSU6JRWK=
SNU-387	NYPiO4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fHXWlEPTB;NT6zNlM{QSEQvF2=	NFnubFZUSU6JRWK=
C8166	NXLxUJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzSZmJKSzVyPUWuN\|Y{OzlizszN	Ml:xV2FPT0WU
LS-1034	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfC[2QyUUN3ME21MlQzOzB5IN88US=>	NY\4dIlyW0GQR1XS
GR-ST	NGTKTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3EWnBKSzVyPUWuOVIzODFizszN	NXfRcFZCW0GQR1XS
NCI-H1092	NHf3[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;wSIp7UUN3ME21MlczQDR\|IN88US=>	MVvTRW5ITVJ?
647-V	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq1WFR2UUN3ME21Mlc1PzB4IN88US=>	NGn2TmZUSU6JRWK=
EW-13	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTVwN{[2Nlch\|ryP	NUGwTIY4W0GQR1XS
KGN	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoC2TWM2OD14LkC5PVIyKM7:TR?=	NY\1NFRrW0GQR1XS
D-423MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHRN2xiUUN3ME22MlQxOjh2IN88US=>	MYDTRW5ITVJ?
ECC10	M2\YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWC4eZh6UUN3ME23MlExOTBzIN88US=>	MofGV2FPT0WU
TE-5	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\4cYZKSzVyPUeuOFEzQThizszN	MnPhV2FPT0WU
P12-ICHIKAWA	NUfjNWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIO2W4dKSzVyPUeuOFU2OjNizszN	NUPy[ZI1W0GQR1XS
NCI-H82	NGfDfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\qTWM2OD15LkS1O\|AyKM7:TR?=	M3fhe3NCVkeHUh?=
NCI-H1993	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTTdFkzUUN3ME23Mlg{ODZ\|IN88US=>	MkLUV2FPT0WU
RH-1	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\nb\|ZKSzVyPUeuPFUzPDRizszN	Mkj1V2FPT0WU
SW948	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[wS4ZKSzVyPUeuPVYxPDlizszN	NETER2ZUSU6JRWK=
CAL-33	NGjaSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3m0e2lEPTB;Nz65PVk{QCEQvF2=	MXnTRW5ITVJ?
U-266	NX[1SI1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TkeWlEPTB;OD6xOVc4PyEQvF2=	MkDHV2FPT0WU
CAL-72	NELTOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojlTWM2OD16LkKwN\|Ih\|ryP	NVjtR5ZlW0GQR1XS
SNU-423	NXKyO2tDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:4TWM2OD17LkO2OlY3KM7:TR?=	MV3TRW5ITVJ?
KG-1	M4fyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDCe25KSzVyPUmuOVg1PTZizszN	M{jpPHNCVkeHUh?=
HCC1395	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTifY1YUUN3ME25MlkzOzV{IN88US=>	NVHNb4pJW0GQR1XS
BE-13	NX3Q[npzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rFdWlEPTB;MUCuPFg6OiEQvF2=	NXjvdJNkW0GQR1XS
MKN7	NHPGO\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH70RpRKSzVyPUGwMlk4PjVizszN	NX;yWnk2W0GQR1XS
697	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFzLkG0O\|Ih\|ryP	M3e2e3NCVkeHUh?=
LU-135	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\zd3JKSzVyPUGxMlI{ODdizszN	M2q3bnNCVkeHUh?=
ES7	M1qwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XERWlEPTB;MUGuN\|MyOyEQvF2=	MonPV2FPT0WU
SK-HEP-1	NFHacoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFzLke2OFYh\|ryP	NXzIVIdHW0GQR1XS
BEN	M4j4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7CTWM2OD1zMT64OVEh\|ryP	NHTvVYpUSU6JRWK=
NCI-H1770	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjOfIhKSzVyPUGyMlEzPiEQvF2=	NELx[mRUSU6JRWK=
SW13	NVvwb4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\o[WlEPTB;MUKuNVU1OSEQvF2=	MX;TRW5ITVJ?
MZ1-PC	NFTvVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r3cWlEPTB;MUKuOVQ2OiEQvF2=	NV\kZo5rW0GQR1XS
Mo-T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TFbGlEPTB;MUKuO\|QzOSEQvF2=	MVHTRW5ITVJ?
HLE	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDD[VVrUUN3ME2xNk45OjF3IN88US=>	NWfWZlN3W0GQR1XS
RCC10RGB	NXvFTG86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjTW4tKSzVyPUGzMlY4OSEQvF2=	NILlbYtUSU6JRWK=
COLO-320-HSR	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnpO2VKSzVyPUGzMlc{QDFizszN	MUPTRW5ITVJ?
BHT-101	NEflO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\yVphKSzVyPUGzMlg{PDVizszN	NYfuUYc{W0GQR1XS
OCUB-M	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\6WIZKSzVyPUG0MlE3ODJizszN	NUDRfoNQW0GQR1XS
MEG-01	NGDsPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTPb5UzUUN3ME2xOE4{PzB6IN88US=>	Mn[xV2FPT0WU
RS4-11	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDTTWM2OD1zND63OFIh\|ryP	NFjKRWNUSU6JRWK=
MN-60	NUTqS2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPNTWM2OD1zND63PFk1KM7:TR?=	MWHTRW5ITVJ?
NCI-H1304	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy2cIhMUUN3ME2xOU4xPDJ3IN88US=>	NXe0WFl4W0GQR1XS
Ramos-2G6-4C10	NIHPNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonhTWM2OD1zNT6wOVgyKM7:TR?=	NHLIW5JUSU6JRWK=
NCI-H2342	NX;DT3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE[2[3pKSzVyPUG1MlIxPDRizszN	MXvTRW5ITVJ?
LAN-6	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLiTWM2OD1zNT60OFE1KM7:TR?=	M3LpT3NCVkeHUh?=
JVM-2	NXz4PGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTF3LkW3OFgh\|ryP	MnXZV2FPT0WU
P30-OHK	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILHc4NKSzVyPUG2MlA3OTRizszN	MXvTRW5ITVJ?
C-33-A	NYD1R29RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7ncXRKSzVyPUG2MlYzOTRizszN	M3HZenNCVkeHUh?=
RPMI-8866	M{e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLmNVZQUUN3ME2xOk45PDl4IN88US=>	M1exUnNCVkeHUh?=
NCI-H630	M3rPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO4WYZKSzVyPUG2Mlg2OzdizszN	NF\KNItUSU6JRWK=
KYSE-140	NXfZdYJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjYfJRKSzVyPUG3MlIxOjhizszN	NULnVZZiW0GQR1XS
T84	NIOzfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[0SXUzUUN3ME2xPE45Pjl3IN88US=>	MVvTRW5ITVJ?
KU-19-19	M1HxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{D5V2lEPTB;MUiuPVYxQCEQvF2=	MoDQV2FPT0WU
BALL-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDZTWM2OD1zOT6zN\|k6KM7:TR?=	MWLTRW5ITVJ?
Calu-6	Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nwSmlEPTB;MUmuOFkzKM7:TR?=	NIrKOVlUSU6JRWK=
EGI-1	NU[yeI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHuwPVJKSzVyPUG5MlU6QCEQvF2=	M3zEeHNCVkeHUh?=
MFH-ino	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFW2[INKSzVyPUG5Mlc1PTRizszN	NW\SVppnW0GQR1XS
GB-1	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHTTWM2OD1{MD6zOVM2KM7:TR?=	NVrIeIZJW0GQR1XS
NCI-H1693	NFz6SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnK1TWM2OD1{MD62OVA2KM7:TR?=	NV2wPIY5W0GQR1XS
SW1116	NX7WVVVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1L1dWlEPTB;MkCuPVM3OiEQvF2=	Mn\lV2FPT0WU
H-EMC-SS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofTTWM2OD1{Mj6wOFUh\|ryP	NUO4dHoyW0GQR1XS
D-502MG	M4XsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ{LkiyOlEh\|ryP	Mk\JV2FPT0WU
IA-LM	M{jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfze\|RKSzVyPUKzMlI1QTNizszN	NHXnTYtUSU6JRWK=
SW1463	M3n3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHLTWM2OD1{Mz63PUDPxE1?	NYj6VZlRW0GQR1XS
JAR	NEjZUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1z5dGlEPTB;MkSuN\|I6OyEQvF2=	NFLVfIlUSU6JRWK=
HT	NHvVU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJ2LkS3OVMh\|ryP	NEDuTXlUSU6JRWK=
LCLC-103H	M{PaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOzN29KSzVyPUK0Mlg1PDlizszN	MXnTRW5ITVJ?
SNU-449	NF;ZUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ2Lki3OFEh\|ryP	MY\TRW5ITVJ?
KE-37	NXj4d3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPVTWM2OD1{NT6wPVI5KM7:TR?=	MWjTRW5ITVJ?
NCI-H1623	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rTcWlEPTB;MkeuNVMxOyEQvF2=	Mnz0V2FPT0WU
MOLT-13	NYXMWW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTwTWM2OD1{Nz6zOVE3KM7:TR?=	NV3xfVk6W0GQR1XS
COLO-741	NWW4SmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4S1SmlEPTB;M{GuN\|M{OyEQvF2=	MlLHV2FPT0WU
NB6	NVTqWW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTN{LkK4O\|Yh\|ryP	NGG2W3JUSU6JRWK=
MOLT-16	NW\ERYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTN\|LkCwOVUh\|ryP	MXrTRW5ITVJ?
IST-MES1	M1i1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jrbGlEPTB;M{SuNFU1OSEQvF2=	MXzTRW5ITVJ?
A4-Fuk	NIHpS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXhUlZKSzVyPUO1MlA3PiEQvF2=	M{HsVHNCVkeHUh?=
CAL-85-1	NGXUTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLXTWM2OD1\|NT6yPFE4KM7:TR?=	NUG1SVEyW0GQR1XS
CCRF-CEM	NXXwV2pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D4SmlEPTB;M{euNVU{PiEQvF2=	NVS0bXRxW0GQR1XS
HAL-01	NGHLN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrSdGRCUUN3ME2zPE41QDh7IN88US=>	M4r3UHNCVkeHUh?=
HEL	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rpO2lEPTB;NEOuN\|QxQSEQvF2=	MoDXV2FPT0WU
EW-1	MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\BTWM2OD12Mz60O\|Y5KM7:TR?=	NYjJRYhZW0GQR1XS
MDA-MB-231	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi2R5hjUUN3ME20OU4yOTl7IN88US=>	MVvTRW5ITVJ?
ABC-1	M4X3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTmS5dKSzVyPUS2Mlg2OzhizszN	MnzJV2FPT0WU
NCI-H446	M3z2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fJT2lEPTB;NEiuOVA2QCEQvF2=	MmjUV2FPT0WU
MHH-PREB-1	M1naOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP1V3NKSzVyPUS5MlYxODdizszN	NXvxO4hxW0GQR1XS
DOHH-2	Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvoUnlKSzVyPUS5MlY3PTZizszN	MXvTRW5ITVJ?
GCT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3DTWM2OD12OT62PVc3KM7:TR?=	NGq2TplUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00354185	Terminated	Adult Nasal Type Extranodal NK/T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	May 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)